December 10, 2014 | BioLight Life Sciences Investments announced that it signed an exclusive distribution agreement for the sale and marketing of the IOPiMate system in Hong Kong and Macao. The IOPiMate system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball. In Hong Kong, the system has been installed in a trial basis in a medical center after received approval in March from the China Food and Drug Administration. BioLight invests in, manages and commercializes biomedical innovations grouped around defined medical conditions, ophthalmology and cancer diagnostics.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments